[Feminishing adrenal tumor with primary hyperaldosteronism. Report of a case (author's transl)].
A case of feminishing adrenal tumor with primary hyperaldosteronism is reported. The aim of this report is to emphasize on the terminal evolution of the disease. This phase was marked by malignant hypertension, severe renal insufficiency, and iatrogenic cellular hyperhydration with hyponatremia secondary to spironolactone therapy.
D000310:Adrenal Gland Neoplasms / Q000150:complications*; D005262:Feminization / Q000209:etiology*; D006801:Humans; D006929:Hyperaldosteronism / Q000209:etiology*; D006973:Hypertension / Q000209:etiology*; D007049:Iatrogenic Disease; D007676:Kidney Failure, Chronic / Q000209:etiology; D008297:Male; D013148:Spironolactone / Q000009:adverse effects; D013577:Syndrome; D013997:Time Factors; D014883:Water-Electrolyte Imbalance / Q000139:chemically induced
D013148:Spironolactone
Tumeur féminisante de la surrénale avec hyperaldostéronisme primaire et hypertension artérielle maligne. Evolution terminale